Pancreatic adenocarcinoma |
-
-
Increased in human pancreatic adenocarcinoma tissues and cell lines.
-
-
Increased in chronic pancreatitis, pancreatic intra-epithelial neoplasms
|
-
-
Required for cellular proliferation and cell cycle progression involving Mg2+.
-
-
Required for preventing replicative senescence.
-
-
Required for cell migration involving Mg2+.
-
-
Required for cell invasion.
|
[9,27,28,29,30,31] |
Breast carcinoma |
-
-
Over-expression in human breast carcinoma tissues and cell lines
-
-
Increased expression in infiltrating ductal carcinoma with microcalcifications
-
-
Somatic mutation T720S (Thr→Ser) in a breast infiltrating ductal carcinoma
|
-
-
Required for cancer cell proliferation in vitro.
-
-
Required for cancer cell migration in vitro and tumor metastasis in a mouse xenograft model.
Waixenicin A, TRPM7 blocker, inhibits growth and survival of breast cancer cells MCF-7.
-
-
TRPM7 involved in estrogen receptor-negative metastatic breast cancer cells migration through kinase domain.
-
-
Involved in ginsenoside Rd-induced apoptosis in cells.
-
-
Involved in epithelial mesenchymal transition.
-
-
TRPM7 mediates migration and invasion of breast cancer cells (MDA-MB-435) involving phosphorylation of Src and MAPK.
|
[32,33,34,35,36,37,38,39,40] |
Gastric carcinoma |
-
-
Expressed in human gastric adenocarcinoma cell lines (AGS, MKN-1, MKN-45, SNU-1, SNU-484)
-
-
Somatic mutation M830V (Met→Val) in gastric adenocarcinoma
|
-
-
Required for cell survival involving Mg2+.
-
-
Waixenicin A, TRPM7 blocker, inhibits growth and survival of gastric cancer cells AGS.
-
-
Involved in ginsenoside Rd-induced apoptosis AGS cells.
|
[37,38,40,41,42,43] |
Head and neck Carcinoma |
-
-
Expressed in FaDu cells and SCC-25 cells.
-
-
High expression in 5-8F cells, low expression in 6-10B cells
|
-
-
Required for cell growth and proliferation.
-
-
Required for migration of nasopharyngeal carcinoma cells (5-8F and 6-10B).
-
-
Proliferation of FaDu hypopharyngeal squamous cells (FaDu) inhibited by midazolam that targets TRPM7.
|
[44,45,46] |
Retinoblastoma |
|
|
[47] |
Melanoma |
|
|
[48,49] |
Lung carcinoma |
|
|
[50] |
Erythroleukemia |
|
|
[51] |
Colon cancer |
|
-
-
TRPM7 (Thr1482Ile) polymorphism associated with elevated risk of both adenomatous and hyperplastic polyps.
-
-
Individuals with TRPM7 (Thr1482Ile) polymorphism with a high Ca:Mg ratio intake in diet at a relatively high risk of developing adenoma and hyperplastic polyps.
|
[52] |
Leukemia |
|
|
[53] |
Neuroblastoma |
|
-
-
In mouse neuroblastoma cells (N1E-115), TRPM7 promotes formation of Ca2+ sparking and invadosome by affecting actomyosin contractility independent from Ca2+ influx.
-
-
In vivo and in vitro studies using N1E-115 cells, TRPM7 promotes tumor metastasis in a mouse xenograft model and cell migration in Boyden chamber.
|
[54,55] |
Ovarian carcinoma |
|
|
[40] |
Prostate cancer |
|
|
[56] |
Glioblastoma |
|
-
-
Carvacrol inhibits TRPM7 and suppresses glioblastoma cell proliferation, migration, and invasion
-
-
Xylokeletal B inhibits TRPM7 and suppresses glioblastoma cell proliferation and migration through PI3K/Akt and MEK/ERK signaling
-
-
Midazolam inhibits TRPM7-mediated current and suppresess TRPM7 expression, and induces cell cycle arrest and impairs proliferation
|
[57,58,59] |